Trial · NCT07477431
Levetiracetam for Persons at Risk for Alzheimer's Disease
NCT07477431, Phase 2, Recruiting, Sunnybrook Health Sciences Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Levetiracetam for Persons at Risk for Alzheimer's Disease. Trials, record NCT07477431. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07477431
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Levetiracetam for Persons at Risk for Alzheimer's Disease
- NCT number
- NCT07477431
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Conditions
- Hippocampal Hyperactivation, Prodromal Alzheimer Disease
- Interventions
- Levetiracetam (LEV), Placebo
- First posted
- 2026-03-17
- Last updated
- 2026-07-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Level of fMRI activity in the hippocampus and entorhinal cortex during a pattern separation task (PST), as a function of LEV vs placebo | Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12) | |
| Secondary | Behavioural performance on the PST as a function of LEV vs placebo | Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12) | Evaluation of participant's ability to correctly discriminate between presented stimuli as old, new, or similar. The lure discrimination index (LDI) is based on the proportion of the presented lures correctly called similar and the proportion of lures incorrectly called old. |
| Secondary | Frequency of epileptiform discharges on EEG as a function of LEV vs placebo | Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12) | Resting-state EEG |
| Secondary | Power spectrum analysis for hippocampus in resting-state MEG as a function of LEV vs placebo | Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12) | Power in specific frequency bands (theta, alpha, beta) will be analyzed. |
| Secondary | Changes in hippocampal signal in MEG during repetition suppression task as a function of LEV vs placebo | Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12) | Beta band power (desynchronization) will be measured with novel versus repeated presentation of images in the repetition suppression task. |
| Other | Assessment of the relative safety and tolerability of LEV compared to placebo | Adverse events will be captured from randomization (Day 0) to study completion (Day 98-119). | The number of adverse events and number of serious adverse events reported will be used to assess the safety of LEV compared to placebo. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Mnemonic Similarity Task | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07477431
GET https://conductscience.org/api/trials/v1/NCT07477431/registered